ANGPTL3 drugs for Homozygous Familial Hypercholesterolemia
2 tracked ANGPTL3 drugs in the Homozygous Familial Hypercholesterolemia race. The class explanation lives on the ANGPTL3 page; the full indication pipeline across every mechanism is on the Homozygous Familial Hypercholesterolemia page.
1 approved / phase 41 Phase 3
Head-to-head evidence: Evinacumab vs SHR-1918